Robert Elsby

2.0k total citations
25 papers, 1.6k citations indexed

About

Robert Elsby is a scholar working on Oncology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Robert Elsby has authored 25 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 11 papers in Pharmacology and 10 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Robert Elsby's work include Drug Transport and Resistance Mechanisms (17 papers), Pharmacological Effects and Toxicity Studies (9 papers) and Pharmacogenetics and Drug Metabolism (9 papers). Robert Elsby is often cited by papers focused on Drug Transport and Resistance Mechanisms (17 papers), Pharmacological Effects and Toxicity Studies (9 papers) and Pharmacogenetics and Drug Metabolism (9 papers). Robert Elsby collaborates with scholars based in United Kingdom, United States and Singapore. Robert Elsby's co-authors include Katherine S. Fenner, Dominic Surry, Constanze Hilgendorf, Neil R. Kitteringham, Pradeep Sharma, James L. Maggs, John Ashby, Christopher E. Goldring, B. Kevin Park and Bruce K. Birmingham and has published in prestigious journals such as Journal of Biological Chemistry, Hepatology and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Robert Elsby

25 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Elsby United Kingdom	20	729	551	367	363	224	25	1.6k
Dylan P. Hartley United States	24	972 1.3×	576 1.0×	708 1.9×	382 1.1×	191 0.9×	41	2.2k
J. Greg Slatter United States	21	666 0.9×	540 1.0×	762 2.1×	166 0.5×	95 0.4×	50	1.9k
Su‐Jun Lee South Korea	24	478 0.7×	806 1.5×	608 1.7×	192 0.5×	101 0.5×	74	1.9k
Matthew G. Soars United States	20	785 1.1×	979 1.8×	378 1.0×	288 0.8×	82 0.4×	32	1.6k
Hongbing Wang United States	20	362 0.5×	655 1.2×	384 1.0×	127 0.3×	103 0.5×	55	1.4k
Alison E.M. Vickers United States	23	330 0.5×	503 0.9×	443 1.2×	138 0.4×	197 0.9×	55	1.5k
David Hallifax United Kingdom	21	809 1.1×	1.2k 2.1×	349 1.0×	233 0.6×	116 0.5×	31	1.8k
Jinghai J. Xu United States	14	416 0.6×	715 1.3×	548 1.5×	191 0.5×	124 0.6×	23	1.8k
Yannick Parmentier France	18	583 0.8×	335 0.6×	265 0.7×	259 0.7×	86 0.4×	38	1.1k
Kathleen M. Hillgren United States	18	823 1.1×	327 0.6×	372 1.0×	424 1.2×	125 0.6×	30	1.4k

Countries citing papers authored by Robert Elsby

Since Specialization

Citations

This map shows the geographic impact of Robert Elsby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Elsby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Elsby more than expected).

Fields of papers citing papers by Robert Elsby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Elsby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Elsby. The network helps show where Robert Elsby may publish in the future.

Co-authorship network of co-authors of Robert Elsby

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Elsby. A scholar is included among the top collaborators of Robert Elsby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Elsby. Robert Elsby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Elsby, Robert, et al.. (2023). Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3. Pharmacology Research & Perspectives. 11(2). e01060–e01060. 6 indexed citations

Elsby, Robert, et al.. (2018). Mechanistic In Vitro Studies Indicate that the Clinical Drug-Drug Interaction between Telithromycin and Simvastatin Acid Is Driven by Time-Dependent Inhibition of CYP3A4 with Minimal Effect on OATP1B1. Drug Metabolism and Disposition. 47(1). 1–8. 13 indexed citations

Martin, Paul, Michael Gillen, James M. Ritter, et al.. (2016). Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies. Drugs in R&D. 16(1). 93–107. 34 indexed citations

Elsby, Robert, Paul Martin, Dominic Surry, Pradeep Sharma, & Katherine S. Fenner. (2015). Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure. Drug Metabolism and Disposition. 44(3). 398–408. 81 indexed citations

Martin, Paul, Michael Gillen, David Millson, et al.. (2015). Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies. Clinical Therapeutics. 37(12). 2811–2822. 15 indexed citations

Birmingham, Bruce K., Sarah R. Bujac, Robert Elsby, et al.. (2015). Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. European Journal of Clinical Pharmacology. 71(3). 329–340. 98 indexed citations

Elsby, Robert, et al.. (2013). The use of bioreactors as in vitro models in pharmaceutical research. Drug Discovery Today. 18(19-20). 922–935. 19 indexed citations

Elsby, Robert, Constanze Hilgendorf, & Katherine S. Fenner. (2012). Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1. Clinical Pharmacology & Therapeutics. 92(5). 584–598. 163 indexed citations

Sharma, Pradeep, et al.. (2012). Prediction of the in vivo OATP1B1-mediated drug–drug interaction potential of an investigational drug against a range of statins. European Journal of Pharmaceutical Sciences. 47(1). 244–255. 43 indexed citations

10.

Elsby, Robert, et al.. (2011). Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug–drug interaction to support regulatory submissions. Xenobiotica. 41(9). 764–783. 28 indexed citations

11.

Elsby, Robert, et al.. (2010). The Utility of In Vitro Data in Making Accurate Predictions of Human P-Glycoprotein-Mediated Drug-Drug Interactions: A Case Study for AZD5672. Drug Metabolism and Disposition. 39(2). 275–282. 19 indexed citations

12.

Sharma, Pradeep, et al.. (2009). Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug–drug interaction to support regulatory submissions. Xenobiotica. 40(1). 24–37. 23 indexed citations

13.

Elsby, Robert, et al.. (2008). Validation and application of Caco-2 assays for thein vitroevaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica. 38(7-8). 1140–1164. 100 indexed citations

14.

Jenkins, Rosalind E., Neil R. Kitteringham, Christie L. Hunter, et al.. (2006). Relative and absolute quantitative expression profiling of cytochromes P450 using isotope‐coded affinity tags. PROTEOMICS. 6(6). 1934–1947. 58 indexed citations

15.

Goldring, Christopher E., Neil R. Kitteringham, Robert Elsby, et al.. (2004). Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. Hepatology. 39(5). 1267–1276. 168 indexed citations

16.

Kitteringham, Neil R., Helen Powell, Rosalind E. Jenkins, et al.. (2003). Protein expression profiling of glutathione S‐transferase pi null mice as a strategy to identify potential markers of resistance to paracetamol‐induced toxicity in the liver. PROTEOMICS. 3(2). 191–207. 31 indexed citations

17.

Elsby, Robert, Neil R. Kitteringham, Christopher E. Goldring, et al.. (2003). Increased Constitutive c-Jun N-terminal Kinase Signaling in Mice Lacking Glutathione S-Transferase Pi. Journal of Biological Chemistry. 278(25). 22243–22249. 128 indexed citations

18.

Elsby, Robert, James L. Maggs, John Ashby, & B. Kevin Park. (2001). Comparison of the Modulatory Effects of Human and Rat Liver Microsomal Metabolism on the Estrogenicity of Bisphenol A: Implications for Extrapolation to Humans. Journal of Pharmacology and Experimental Therapeutics. 297(1). 103–113. 91 indexed citations

19.

Elsby, Robert, et al.. (2001). Assessment of the Effects of Metabolism on the Estrogenic Activity of Xenoestrogens: A Two-Stage Approach Coupling Human Liver Microsomes and a Yeast Estrogenicity Assay. Journal of Pharmacology and Experimental Therapeutics. 296(2). 329–337. 32 indexed citations

20.

Elsby, Robert, John Ashby, John P. Sumpter, et al.. (2000). Obstacles to the prediction of estrogenicity from chemical structure: assay-mediated metabolic transformation and the apparent promiscuous nature of the estrogen receptor. Biochemical Pharmacology. 60(10). 1519–1530. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact